Latest & greatest articles for sertraline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sertraline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sertraline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sertraline

21. Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents

Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents Article Text Therapeutics Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents Statistics from Altmetric.com No Altmetric data available for this article. QUESTION

Evidence-Based Mental Health2009

22. A combination of cognitive?behavioural therapy and sertraline reduced anxiety in children more than either treatment alone

A combination of cognitive?behavioural therapy and sertraline reduced anxiety in children more than either treatment alone A combination of cognitive–behavioural therapy and sertraline reduced anxiety in children more than either treatment alone | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A combination of cognitive–behavioural therapy and sertraline reduced anxiety in children more than either treatment alone Article Text Therapeutics A combination of cognitive–behavioural therapy and sertraline reduced anxiety in children more than either

Evidence-Based Medicine (Requires free registration)2009

23. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.

Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. 19843899 2009 10 21 2009 11 02 2016 10 19 1538-3598 302 15 2009 Oct 21 JAMA JAMA Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. 1651-7 10.1001/jama.2009.1487 Studies of depressed psychiatric patients have shown that antidepressant efficacy can be increased by augmentation (...) with omega-3 fatty acids. To determine whether omega-3 improves the response to sertraline in patients with major depression and coronary heart disease (CHD). Randomized controlled trial. Between May 2005 and December 2008, 122 patients in St Louis, Missouri, with major depression and CHD were randomized. After a 2-week run-in period, all patients were given 50 mg/d of sertraline and randomized in double-blind fashion to receive 2 g/d of omega-3 acid ethyl esters (930 mg of eicosapentaenoic acid [EPA

JAMA2009 Full Text: Link to full Text with Trip Pro

24. Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response

Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response Article Text Therapeutics Group cognitive

Evidence-Based Mental Health2008

25. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.

Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. 18974308 2008 12 25 2009 01 06 2016 12 15 1533-4406 359 26 2008 Dec 25 The New England journal of medicine N. Engl. J. Med. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. 2753-66 10.1056/NEJMoa0804633 Anxiety disorders are common psychiatric conditions affecting children and adolescents. Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown (...) efficacy in treating these disorders, little is known about their relative or combined efficacy. In this randomized, controlled trial, we assigned 488 children between the ages of 7 and 17 years who had a primary diagnosis of separation anxiety disorder, generalized anxiety disorder, or social phobia to receive 14 sessions of cognitive behavioral therapy, sertraline (at a dose of up to 200 mg per day), a combination of sertraline and cognitive behavioral therapy, or a placebo drug for 12 weeks in a 2:2

NEJM2008 Full Text: Link to full Text with Trip Pro

26. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder

Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Armstrong E P, Skrepnek G H, Erder M H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two selective serotonin re-uptake inhibitors (SSRIs), escitalopram and sertraline, for the treatment of major depressive disorder (MDD). Escitalopram was initially given at 10 mg/day; the dose was assumed to increase to 20 mg/day if the patient did not respond to the initial dose. Sertraline was initially given at 50 mg/day

NHS Economic Evaluation Database.2007

27. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Article Text Therapeutics Major depressive disorder: similar remission rates

Evidence-Based Mental Health2006

28. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 16554525 2006 03 23 2006 04 07 2015 11 19 1533-4406 354 12 2006 Mar 23 The New England journal of medicine N. Engl. J. Med. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 1231-42 After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. We (...) randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care

NEJM2006

29. Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status

Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status Article Text Therapeutics Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status Free Ilsemarie

Evidence-Based Mental Health2005

30. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents

Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Article Text Therapeutics Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Free Lon S Schneider , MD Statistics

Evidence-Based Mental Health2005

31. Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder

Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder Article Text Therapeutics Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder Free John March , MD Statistics from Altmetric.com No Altmetric data available for this article. Wagner KD

Evidence-Based Medicine (Requires free registration)2005

32. Sertraline improves symptoms in children and adolescents with major depressive disorder

Sertraline improves symptoms in children and adolescents with major depressive disorder Sertraline improves symptoms in children and adolescents with major depressive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline improves symptoms in children and adolescents with major depressive disorder Article Text Therapeutics Sertraline improves symptoms in children and adolescents with major depressive disorder Free Erin B McClure , PhD , Ellesn Leibenluff , MD , Daniel S Pine , MD Statistics from Altmetric.com No Altmetric data

Evidence-Based Mental Health2005

33. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction

Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction O'Connor C M, Glassman A H, Harrison D J Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of 24 weeks' sertraline, a selective serotonin reuptake inhibitor, for the treatment of depressive disorders in patients with unstable angina (UA) or a recent myocardial infarction (MI). Sertraline was initially given at a dosage of 50

NHS Economic Evaluation Database.2005

34. The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia

The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia Article Text Therapeutics The benefits of exposure therapy alone may last longer than sertraline alone or sertraline

Evidence-Based Mental Health2004

35. Sertraline as a treatment for PTSD: a systematic review and meta-analysis

Sertraline as a treatment for PTSD: a systematic review and meta-analysis Sertraline as a treatment for PTSD: a systematic review and meta-analysis Sertraline as a treatment for PTSD: a systematic review and meta-analysis Mooney P, Oakley J, Ferriter M, Travers R CRD summary This review assessed the effectiveness of sertraline for the treatment of post-traumatic stress disorder. The authors concluded that there is evidence to support the use of sertraline, but further research is required (...) . Although there were a number of limitations to this review, the authors' conclusions appear appropriately cautious. Authors' objectives To assess the effectiveness of sertraline for the treatment of post-traumatic stress disorder (PTSD). Searching PsycINFO, MEDLINE, EMBASE, the National Centre for PTSD and the Cochrane Library were searched using the reported search terms. The references of included and excluded studies were checked for further primary studies. Study selection Study designs

DARE.2004

36. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.

Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. 15507582 2004 10 27 2004 11 01 2016 10 19 1538-3598 292 16 2004 Oct 27 JAMA JAMA Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. 1969-76 The empirical (...) literature on treatment of obsessive-compulsive disorder (OCD) in children and adolescents supports the efficacy of short-term OCD-specific cognitive-behavior therapy (CBT) or medical management with selective serotonin reuptake inhibitors. However, little is known about their relative and combined efficacy. To evaluate the efficacy of CBT alone and medical management with the selective serotonin reuptake inhibitor sertraline alone, or CBT and sertraline combined, as initial treatment for children

JAMA2004

37. Sertraline (Lustral)

Sertraline (Lustral) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Sertraline (Lustral Ò ) (No. 68/03) Pfizer Ltd Summary of Recommendation 10 November, 2003 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised (...) as follows: Advice: following a full submission. Not recommended for use within NHS Scotland. Sertraline has demonstrated some benefit in treating post-traumatic stress disorder (PTSD) in two of four 12-week double blind treatment studies, and in extension studies for up to 64 weeks. The product licence restricts its use to women only; a narrower indication than for the other drug currently licensed for treating PTSD, and against which no comparative trials has been conducted. The manufacturer submitted

Scottish Medicines Consortium2003

38. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.

Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. 12941675 2003 08 27 2003 09 02 2016 10 17 1538-3598 290 8 2003 Aug 27 JAMA JAMA Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. 1033-41 The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive (...) disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents. To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD. Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled

JAMA2003

39. Sertraline: a review of its use in the management of major depressive disorder in elderly patients

Sertraline: a review of its use in the management of major depressive disorder in elderly patients Sertraline: a review of its use in the management of major depressive disorder in elderly patients Sertraline: a review of its use in the management of major depressive disorder in elderly patients Muijsers RB, Plosker GL, Noble S Authors' objectives The authors' objective appeared to be to assess the efficacy of sertraline in elderly people with major depressive disorder. The review also includes (...) evidence on the pharmacodynamics and pharmacokinetic profile of sertraline. This abstract refers only to that part of the review dealing with the therapeutic use of sertraline. Searching MEDLINE, EMBASE and AdisBase were searched from 1980 to May 2002; the search terms were reported. In addition, the bibliographies of published articles were reviewed for further studies. Bibliographic information, including contributory unpublished data, were also requested from the company developing the drug

DARE.2002

40. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs

Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal (...) examined in the study were Sertraline (SER), a selective serotonin reuptake inhibiting (SSRI) antidepressant (starting dose: 50 mg daily); Interpersonal Psychotherapy (IPT); and a combination of both (SER-IPT) for the treatment of adult patients with dysthymia. Patients were treated for six months with one of the three alternative interventions, which was then followed by an additional naturalistic 18-month follow-up. However, patients receiving SER would continue taking their medication until the end

NHS Economic Evaluation Database.2002